Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rimexolone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rimexolone | DRUG | - |
Inclusion Criteria: * documented dry eye history * ocular symptoms * tear use * dry eye ocular signs Exclusion Criteria: * Under 18
Rimexolone is being developed for the treatment of dry eye, an ophthalmology condition. It is a small molecule drug candidate that has been studied in a Phase 3 clinical trial in adults with dry eye. Alcon Inc. is the developer.
Rimexolone targets NR3C1, also known as the glucocorticoid receptor. It acts as an agonist at this receptor. This target class is relevant to inflammatory pathways in ophthalmology, including dry eye.
Rimexolone is being developed by Alcon Inc., which trades under the ticker ALC. Alcon is an ophthalmology-focused pharmaceutical company. The drug is in Phase 3 development for dry eye.
Rimexolone is in Phase 3 clinical development for dry eye. It is an investigational drug and has not been approved by the FDA for this indication. The Phase 3 trial has been completed.
Rimexolone has been studied in one completed Phase 3 trial, NCT00471419, titled Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye. The trial enrolled 750 participants in the United States and was randomized and double-blind.
Yes, Rimexolone has also been referred to as AL-2178 and FID 109980 in its clinical development. These alternative names appear in the trial title for NCT00471419, which evaluated the drug in dry eye.